Stockreport

Epizyme Announces FDA Acceptance of New Drug Application for Filing with Priority Review for TAZVERIK™ (tazemetostat) for the Treatment of Follicular Lymphoma

Epizyme, Inc.  (EPZM) 
Last epizyme, inc. earnings: 2/24 06:30 am Check Earnings Report
US:NASDAQ Investor Relations: epizyme.com
PDF Approval Would Expand TAZVERIK™ Label into Second IndicationPDUFA Target Action Date Scheduled for June 18, 2020 CAMBRIDGE, Mass.--(BUSINESS WIRE)--Epizyme, Inc. (Nas [Read more]